#Poland #Clinical Trials #Kraków #Julius Clinical

Julius Clinical Strengthens its European Footprint

Julius Clinical, renowned for its science-driven approach, has recently announced the establishment of a new operational hub in Krakow, Poland. This strategic expansion not only reinforces the company's leadership in the realms of Central Nervous System (CNS) and Cardio-Metabolic research but also significantly enhances its capabilities across European clinical trials.

Over the past several years, Poland has emerged as a key player in clinical research, with Julius Clinical conducting more than 15 trials within the country. The nation boasts a highly-skilled workforce, robust healthcare infrastructure, and a proven dedication to clinical research, making it an ideal location for growing the company’s European operations. The new operations in Krakow allow for more efficient patient recruitment, better site selection, and seamless regulatory compliance, all of which accelerate the transformative research and development of innovative therapies.

Leadership Vision
Martijn Wallert, the CEO of Julius Clinical, expressed that this expansion represents a critical milestone for the company. He noted that expanding into Poland strengthens their presence in Eastern Europe, positioning the country as a central hub for regional operations. Wallert highlighted the importance of this move in supporting clinical research not just across Poland but throughout neighboring countries as well.

Local Expertise
With Radek Korba serving as the Country Manager for Poland, the company is well poised for success. Korba has extensive experience collaborating with Julius Clinical and is enthusiastic about driving forward local operations. He stated, “Poland is a pivotal market in clinical research, and our presence here enables us to foster innovative approaches while adhering to stringent quality and compliance standards. We eagerly anticipate enhancing collaboration with local investigators, healthcare institutions, and regulatory bodies to facilitate impactful research.”

Global Commitment
Julius Clinical's foray into Poland is part of a broader mission to provide exemplary, scientifically-driven clinical research services on a global scale. This venture exemplifies the company's commitment to advancing medical breakthroughs through state-of-the-art trial designs and access to diverse patient populations.

Backing from Ampersand Capital Partners
Julius Clinical receives vital support from Ampersand Capital Partners, a prestigious private equity firm with a robust focus on the life sciences and healthcare sectors. This partnership further solidifies Julius Clinical’s capacity to innovate and lead in the clinical research community.

About Julius Clinical
Founded in 2008 in Zeist, Netherlands, Julius Clinical has established itself as a frontrunner in the field of clinical research, specializing in CNS, Cardio-Metabolic, Renal, and Rare Diseases. With more than 380 clinical trials conducted and over 220,000 subjects enlisted across 39 countries, the company merges scientific leadership with operational excellence, providing tailored solutions to pharmaceutical, biotechnology, and academic partners.

For more detailed insights into Julius Clinical’s services, the community can visit their official website or follow them on LinkedIn. The company's combination of advanced scientific knowledge and commitment to clinical research paves the way for significant advancements in healthcare and therapeutic solutions.

About Ampersand Capital Partners
Established in 1988, Ampersand Capital Partners focuses on growth-oriented investments in healthcare, managing $3 billion in assets. With offices located in both Boston and Amsterdam, the firm brings a blend of private equity expertise and operational insight to drive long-term performance and value across its portfolio.

Visit their website or connect with them on LinkedIn for more information on their operations and investment philosophy.